Ayala's Cancer Candidate Shrinks Tumor In Substantially All Patients In Late-Stage Study

  • Ayala Pharmaceuticals Inc AYLA announced interim results from Part A of the ongoing RINGSIDE Phase 2/3 trial evaluating AL102 in desmoid tumors. 
  • MRI scans showed decreases in tumor size in most of the 13 patients who had reached the 16-week point.
  • One patient reached an unconfirmed partial response at week 16.
  • AL102 was well tolerated at all dose levels with no dose-limiting toxicities, and no Grade 4/5 adverse events were observed.
  • Also Read: Ayala Pharma Unveils New Interim Data From Rare Cancer Trial With AL101.
  • The most common treatment-related adverse events were Grade 1-2, including diarrhea, fatigue, skin rash, and nausea.
  • "We are also encouraged with the safety data showing that AL102 appears well tolerated. We look forward to presenting a more advanced and comprehensive data set at a medical meeting later in the year," said Roni Mamluk, CEO of Ayala. 
  •  "The results from Part A will be used to determine the dose of AL102 to be evaluated in Part B of RINGSIDE, which Ayala is on track to initiate in Q3 of 2022," the CEO added.
  • Price Action: AYLA shares are down 2.05% at $1.09 during the market session on the last check Tuesday.

Posted In: BriefsBiotechNewsPenny StocksHealth CareGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.